OSR Holdings, Inc. Annual Report: A Plain-English Guide

I’ve put together this guide to help you understand how OSR Holdings performed this year. My goal is to translate complex filings into simple terms so you can decide if this company fits your investment goals.

1. What does this company do?

Think of OSR Holdings as a parent company supporting three specialized healthcare "spokes":

• Cancer Immunotherapy (Vaximm): They are developing oral vaccines. The VXM01 platform uses a modified bacteria to train the immune system to attack tumors.
• Degenerative Diseases (Darnatein): They are creating human proteins to help treat osteoarthritis and bone fractures by encouraging bone growth.
• Medical Device Distribution (RMC): This arm operates in South Korea, managing the supply chain for high-end surgical tools and orthopedic implants.

2. A Year of Transformation

2025 was a turning point. The company moved from a SPAC structure to an active healthcare business. They are now focused on advancing 10 patent families across the U.S., Europe, and Asia to protect the rights to their VXM01 vaccine and their protein synthesis process.

3. The "Science Bets" & Competition

The company is making two major "science bets," but they face stiff competition from industry leaders.

• Cancer Vaccine (VXM01): Early trials show the vaccine is safe. OSR is competing against established players like AstraZeneca, who have similar treatments in late-stage trials. Success depends on OSR proving their specific vaccine platform is effective.
• Bone Regeneration (DRT-101 & DRT-102): These are designed as safer alternatives to current bone-graft treatments. They enter a market currently dominated by Medtronic’s Infuse Bone Graft. OSR’s success hinges on demonstrating that their product causes fewer side effects, such as unwanted bone growth.

4. The New Strategy: "4PL" Logistics

The most concrete part of their business is the shift in their medical device arm (RMC). They are moving from simple distribution to a "4PL" platform, where they will manage the entire supply chain, inventory, and billing for Korean hospitals.

• The Goal: Management expects revenue to grow from 4.1 billion KRW in 2026 to 44.8 billion KRW by 2030.
• The Timeline: This revenue growth is projected to begin in 2027. Until then, the division is expected to operate at a loss while the company builds the necessary IT and warehouse infrastructure.

5. Financial Health & Risks

• The Profitability Gap: The company is currently in a "spending" phase. They reported an operating loss this year, driven by over 2.5 billion KRW in research costs. They currently burn about 200 million KRW per month to fund trials and operations.
• The "Cash Gap" Risk: The company faces a timing mismatch. They must pay foreign suppliers in 30–60 days, while Korean hospitals typically take 150–180 days to pay them. This 90-to-120-day gap requires the company to rely on external financing or share issuance to maintain operations.
• Operational Dependencies: Because they do not manufacture their own drugs, they rely on third-party partners. Any disruption at those facilities would halt their development progress.

6. The Bottom Line

OSR is a high-risk, high-reward opportunity. They are attempting to bridge the gap between expensive, long-term drug development and a plan to scale medical logistics in Korea.

Key Takeaway for Investors: The central question is whether the logistics business can scale quickly enough to generate the cash required to fund the company’s research pipeline before they need to raise additional capital. If you are considering an investment, monitor their ability to secure logistics contracts and their cash burn rate in upcoming quarterly updates.